New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

New guidelines published by Obesity Canada take a deep dive into pharmacotherapy and feature the latest recommendations on comorbidities and decision tools. To better understand the impact of these guidelines, Dr. John Buse speaks with one of the guidelines authors, Dr. Sue Pedersen, a specialist in endocrinology and metabolism.

New research on once-daily semaglutide for adolescent patients with obesity may alter clinicians’ approach to care. What do we need to know? Dr. John Buse speaks with one of the study’s investigators, Dr. Silva Arslanian, from the University of Pittsburgh to dive into this clinical data and explore how these results may change the treatment landscape.

What does the latest research on glycemia reduction show us about the impact of glucose-lowering medication in combination with metformin on microvascular and cardiovascular outcomes in patients with type 2 diabetes? Dr. John Buse speaks with one of the study’s investigators, Dr. Jennifer Green, a Professor of Medicine at Duke University, about this emerging data.

The GRADE study demonstrated the efficacy of different treatment options for patients with type 2 diabetes. To learn more about these treatment options, Dr. John Buse joins one of the study’s investigators, Dr. Deborah Wexler from Harvard Medical School and the Massachusetts General Hospital Diabetes Center, to dive into this study.

Research continues to emerge on the bionic pancreas and its capabilities, and a recent study shows how it can count carbohydrates and lower A1c for patients with type 1 diabetes. To find out how it does, Dr. John Buse is joined by Dr. Steven Russell, an Associate Professor of Medicine at Harvard Medical School at the Massachusetts General Hospital.

Recent research has explored the efficacy of open source automated insulin delivery devices for patient with type 1 diabetes. What did these results tell us? Dr. John Buse speaks with Dr. Martin de Bock, a pediatric endocrinologist at the University of Otago in Christchurch, New Zealand, to dive deeper into this research.

Can telehealth change the way we manage persistently controlled type 2 diabetes (PPDM)? Dr. John Buse speaks with Dr. Matt Crowley, an Associate Professor of Medicine in the Department of Medicine in the Division of Endocrinology, Metabolism and Nutrition at Duke University, to explore some of the research on different methods of telehealth.

Food assistance programs like the Supplemental Nutrition Assistance Program (SNAP) can help relieve food insecurity. But can they also lower healthcare spending? To answer this question, Dr. John Buse sits down with Dr. Seth Berkowitz from the Division of General Medicine and Clinical Epidemiology at the University of North Carolina School of Medicine.

Researchers from the GRADE study zeroed in on islet autoimmunity in beta cell dysfunction for patients with type 2 diabetes. What did various treatment options show us? Dr. John Buse speaks with Dr. Ashok Balasubramanyam, a Professor in the Department of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine.